发布时间：2008.7

摘要

Countries covered: Poland

Growth in Poland’s drug market in local currency terms is set to slow down over the next few years butshould return to strength by the end of the forecast period. The main deflationary factors include thegovernment stockpiling the reimbursement list with generics, at the expense of patented pharmaceuticals,and the possibility of even more stringent price restrictions. However, by 2012 growth should hit almost6% in nominal terms, outpacing the rest of the economy, driven by rising GDP and increased consumerspending power.

In March 2008, the Ministry of Health has released a list of pharmaceutical and medical products eligiblefor full or partial reimbursement, along with the proposed reimbursement sums for each drug class. Thisdeclaration of reimbursement figures is a change from previous policy, in which the reimbursement levelswere calculated in relation to the cheapest drug in a particular class. As expected, the new list has facedstrong criticism from multinational drugmakers who believe that the measures are anti-competitive, andare fearful that the authorities are moving towards a system in which only one drug will be reimbursed ineach therapeutic class.

In terms of company activity, this quarter has been quiet, with Hungary’s Richter still digesting Polishdrugmaker Polpharma after its multibillion move for the company at the end of 2007. BMI is confidentthat the deal will close by the end of this quarter after Polish regulators recently approved the transaction.However, this has yet to spark a consolidation scramble amongst local manufacturers. Not thatconcentration is always a good thing. In fact, regulators are considering re-working legislation concerningdrug distribution as they concerned that the major players have too strong a position and are stifling freecompetition.

Meanwhile, Poland has slipped two places to joint 11th in the Business Environment Rankings, due toimprovements in competing markets. Poland has actually increased its score compared to the last quarterdue to a strengthening of its economic structures, as perceived by our Country Risk team. However,corruption remains a problem as underlined by a recent scandal involving prescription fraud on thereimbursement list.

目录及图表